HK Stock Market Move | INNOGEN-B (02591) surged over 9% in the morning session, with the founder and several senior management members making a voluntary commitment to refrain from selling shares.

INNOGEN-B (02591) surged over 9% in the morning session. As of the time of writing, it has risen by 9.61%, trading at HKD 3.765, with a trading volume of HKD 23.90 million. On the news front, Wang Qinhua, the founder, chairman, executive director, general manager, and major shareholder of Yinnuo Pharmaceutical; Jiang Fan, executive director, shareholder of Hong Kong Yiyun and limited partner of the companys employee incentive platform Guangzhou Nopa; Xu Wenjie, executive director and limited partner of Guangzhou Nopa; and Huang Bing, executive director and limited partner of Guangzhou Nopa, have each voluntarily committed not to sell any shares or rights of the company directly or indirectly owned by them for a period of six months starting from August 15. It is worth noting that Yinnuo Pharmaceutical announced at the end of last month that it plans to spend HKD 50 million to repurchase its H-shares in the market. The board believes that conducting this proposed H-share repurchase under the current circumstances demonstrates the company's confidence in its business outlook and prospects, which will ultimately benefit the company and create value for shareholders.